1INTRODUCTIONLung cancer is a major cause for cancer‐related death globally. Although small cell lung cancer (SCLC) accounts for only 15% of all lung cancers, it is a rapidly progressive and often fatal form of lung cancer. Traditionally, the Veterans Administration Lung Cancer Study Group staging system was used to categorize SCLC into two stages; limited stage (LS), defined as any tumor that can be encompassed within one radiation field or is limited to a single hemithorax, while extensive stage (ES) is defined as any disease extending beyond the extent of LS. Cure in SCLC is possible only in a small proportion of patients with median survival in LS ranging from 16 to 24 months. In comparison, patients with ES‐SCLC, the survival rate is much poorer and is in the order of 6–12 months with palliative chemotherapy (CT). There has been little advancement in new therapies for this group of patients.Currently, there are no well‐established biomarkers available in SCLC that could be used as a surrogate marker to determine the likelihood of survival outcome and treatment response to potential life‐extending therapies in SCLC. High serum lactate dehydrogenase (s‐LDH) has in the past been shown in other studies to confer prognostic
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud